How Are Children Affected by Familial Dilated Cardiomyopathy
Introduction
Reports from the National Eye, Lung, and Blood Constitute-funded Pediatric Cardiomyopathy Registry (PCMR) have shown that dilated cardiomyopathy (DCM) is diagnosed in 0.57 of every 100 000 children per year in the United States and has a 5-year chance of death or heart transplantation of 46%.ane,2 These results are consistent with those from pediatric cohort studies in Australia and Finland.3,iv
Run across Clinical Perspective
In adults, DCM occurs mainly secondary to coronary artery disease.5 In children, DCM has a wide spectrum of causes: myocarditis, neuromuscular disease, inborn errors of metabolism, malformation syndromes, familial dilated cardiomyopathy (FDCM) and secondary forms caused by ecology or therapeutic exposures, endocrine affliction, although nearly 70% of cases are categorized as idiopathic.one
Over the past 30 years, outcomes of children with cardiomyopathy take improved piffling and but by the introduction of heart transplantation.6 In a previous study, Towbin et al1 found that the five-year survival of children with DCM varied depending on cause, with the all-time clinical outcomes observed in children with FDCM (94%), and the worst in children with neuromuscular disorders (57%). Survival of children with idiopathic disease and malformation syndromes was intermediate (76% for both).i Unfortunately, the same study found that a cause of DCM was identified in only 34% of children, although comprehensive pathogenic testing was non e'er conducted.1,seven Some other report from the PCMR, using competing risks analysis, showed that children who had FDCM at the time of diagnosis had a lower death charge per unit only a similar transplant rate at 5 years after diagnosis when compared with idiopathic dilated cardiomyopathy (IDCM).viii
Equally previous studies accept suggested that outcomes in children with DCM are related to the pathogenesis of DCM, improving the power to identify the underlying crusade of the affliction could better risk estimates and treatment strategies. Knowing the underlying crusade of DCM is also a prerequisite for risk assessment for family members. Therefore, we undertook a new PCMR analysis comparing children with FDCM to children with IDCM with a documented negative family history.
We hypothesized that transplant-complimentary survival (absence of death or heart transplantation) at the fourth dimension of last follow-upwards would be meliorate in children with FDCM than in those with IDCM. Using information from the PCMR, we likewise identified and compared the predictors of the combined end betoken of decease or transplant of children with FDCM to those with IDCM.
Methods
The PCMR is a cooperative endeavour of most 100 centers in the The states and Canada that enrolled children with principal cardiomyopathy betwixt Jan 1990 and February 2009. The PCMR pattern and implementation are described in detail elsewhere.two The report was approved by an institutional review commission and the subjects gave informed consent.
Briefly, children aged <eighteen years, newly diagnosed with cardiomyopathy at participating centers, were eligible for inclusion. Children were ineligible if they had a specific secondary crusade of DCM, such as pulmonary parenchymal or vascular disease, endocrine disease, rheumatic disease, immunologic disease, cardiotoxic exposures, or a built cardiovascular malformation, that occurred independently of a malformation syndrome. All participating centers obtained Institutional Review Board approval to enroll patients in the registry.
Demographics, family unit history, vital and transplant status, and clinical information relevant to cardiomyopathy, including echocardiographic measurements, were collected at diagnosis and annually thereafter.
For the nowadays analysis, the diagnosis of DCM (divers as a DCM phenotype without a mixed phenotype such as DCM with hypertrophic or restrictive features or coexisting left ventricular [LV] noncompaction) was determined using strict echocardiographic criteria, including evidence of LV dilation and systolic dysfunction, semiquantitative echocardiographic patterns of DCM, a confirmed DCM diagnosis by autopsy or endomyocardial biopsy, or other compelling clinical evidence of DCM.i Familial DCM was divers as a patient with a clinical diagnosis of FDCM documented in the medical tape by the treating cardiologist at the last known follow-upwards or at least one or more affected family members (regardless of age) noted in the medical record. This report is based on the analysis of the results from the PCMR database as of January xiv, 2013.
Written report Variables
Demographic variables included age, sex, and race/ethnicity. Congestive heart failure (CHF) at diagnosis, as indicated in the medical record, and a family unit history of sudden decease were besides included in analyses. Echocardiographic measurements, including LV end-diastolic dimension (LVEDD) and cease-systolic dimension, LV stop-diastolic posterior wall thickness, end-diastolic septal thickness, and LV mass were expressed as z scores relative to body expanse in normal children9; LV fractional shortening (LVFS) and LV ejection fraction (LVEF) were expressed as age-adjusted zscores.10 Data on the presence of atrial enlargement (left, right, or both), and LVEF were available for less than half of children so were non analyzed farther.
Statistical Methods
A Fisher verbal test was used to compare the frequencies of categorical variables; Student's t test (for variables with normal distributions) and the Wilcoxon rank-sum examination (for variables with other continuous distributions) were also used to evaluate differences by the presence or absence of FDCM.
The Kaplan–Meier method was used to estimate the incidence of the composite finish point of the earliest occurring of pretransplant death and cardiac transplant. The 2 components of the blended, pretransplant bloodshed and transplant, were analyzed using cumulative incidence functions, equally death is a competing risk to the occurrence of transplant, with the utilize of Gray's test11 for hypothesis testing. Regression modeling to compare the incidence of pretransplant death and the incidence of transplant betwixt the FDCM versus IDCM groups was conducted using the subdistribution risk model methodology of Fine and Grayness.12 Similarly, the echocardiographic outcomes were analyzed in a competing risks framework with the methodology described above.xiii The component outcomes were echocardiographic normalization, pretransplant decease/transplant composite, and persistently abnormal echocardiogram. Echocardiographic normalization was defined as having both LVEDD <2 standard deviations above normal for body surface area (LVEDD z score <ii) and LVFS or LVEF <2 standard deviations below normal for age (LVFS or LVEF z score >−2).
Cox proportional hazards regression modeling was used to assess FDCM versus IDCM differences in the blended outcome of death/transplant, and to place the factors that were univariately associated with the blended end point. To determine whether the predictors of death/transplant differed for FDCM and IDCM, each covariate was tested for interaction. Multivariable modeling was used to place contained predictors of expiry/transplant. The multivariable model selection procedure included all variables with a univariate P value <0.xx, with the exception of medications at diagnosis, left or right atrial enlargement, and ejection fraction because of the large number of missing values for these variables. The process to construct appropriate covariate-adjusted models included all variables with an FDCM versus IDCM univariate P value <0.10. However, LVEDD rather than LV terminate-systolic dimension was used for final models because of missing information in the latter.
Alpha was set at 0.05, and all tests were ii-tailed. Data were analyzed with the Statistical Analysis System statistical software plan, version 9.3 (SAS Found, Cary, NC), the free software package R "cmprsk" and Due south-PLUS version 6.ane (Insightful Corporation, Seattle, Washington, DC).
Results
Demographic and Clinical Characteristics
Equally of January 2013, 1834 children with DCM were enrolled in the PCMR. Of these, 223 were identified as having FDCM and 647 as having IDCM every bit of their final follow-upward visit. We excluded 964 patients: 357 whose family unit history was unknown, 153 with a diagnosis of IDCM who were found to have some other crusade (myocarditis, inborn errors of metabolism, malformation syndromes, and neuromuscular disorders) at follow-upwardly, and 454 children in whom a specific crusade (other than FDCM) was identified at clinical presentation. The median follow-upwardly fourth dimension of patients who did not attain an finish point of death or transplantation (nontransplanted survivors) was iii.7 years (interquartile range [IQR]: 1.0–6.9 years) for the FDCM group and 2.1 years (IQR: 0.half-dozen–5.1) for the IDCM group. The median follow-up time for the entire cohort beyond both groups was ii.4years (IQR: 0.eight–v.half dozen).
Children with FDCM were significantly older at presentation than children with IDCM (median, three.3 years [IQR: 0.iii–12.1] versus 1.0 year [IQR: 0.3–9.two]), less likely to take CHF at diagnosis (64.1% versus 78.2%, P<0.001), and more likely to have a family history of sudden decease (39.0% versus 2.v%, P<0.001; Table one). Children with FDCM also had significantly lower hateful zscores for LVEDD (P=0.006), and significantly college mean zscores for end-diastolic septal thickness (P=0.034), LVFS (P<0.001), and LVEF (P=0.008; Table 1). Compared to children with FDCM, children with IDCM were significantly more likely to receive whatever cardiac medication at diagnosis (95.eight% versus 91.four%, P=0.03) and antiarrhythmic therapy (23.5% versus xiii.7%, P=0.02).
| Characteristic | Overall | FDCM | IDCM | P Value* |
|---|---|---|---|---|
| north† | 870 | 223 | 647 | |
| Historic period at diagnosis | ||||
| Mean (standard deviations), y | iv.9 (5.9) | 6.two (half-dozen.4) | 4.5 (five.8) | 0.001 |
| Median (IQR), y | 1.2 (0.3–ten.iii) | 3.3 (0.three–12.1) | 1.0 (0.3–ix.ii) | 0.04 |
| Age <one y at diagnosis, % | 47.four | 42.2 | 49.2 | 0.07 |
| Male, % | fifty.6 | 54.7 | 49.1 | 0.16 |
| Race/ethnicity, % | 0.06 | |||
| White | 54.2 | 60.ane | 52.2 | |
| Black | 21.2 | 16.1 | 23.0 | |
| Hispanic | 17.three | xv.1 | 18.0 | |
| Other | 7.3 | 8.vii | 6.8 | |
| Congestive heart failure at diagnosis, % | 74.6 | 64.one | 78.two | <0.001 |
| Family history of sudden decease, % (total north) | x.5 (727) | 39.0 (159) | 2.5 (568) | <0.001 |
| Left ventricular echocardiographic z scores, hateful (standard deviations) | ||||
| End-diastolic dimension (total n=699, 175, and 524) | 4.71 (ii.60) | 4.12 (two.61) | 4.91 (2.57) | <0.001 |
| Stop-systolic dimension (full n=614, 160, and 454) | 6.35 (3.00) | 5.79 (2.89) | six.55 (three.01) | 0.006 |
| Partial shortening (total n=713, 183, and 530) | −8.74 (3.95) | −7.85 (3.98) | −9.06 (iii.89) | <0.001 |
| Terminate-diastolic posterior wall thickness (total n=553, 145, and 408) | −0.threescore (2.58) | −0.63 (2.66) | −0.59 (2.56) | 0.86 |
| Finish-diastolic septal thickness (full north=515, 126, and 389) | −0.98 (1.92) | −0.67 (1.99) | −i.09 (1.88) | 0.03 |
| Mass (total n=545, 143, and 402) | 2.49 (ii.78) | 2.32 (iii.08) | 2.55 (2.67) | 0.43 |
| Medications at diagnosis (due north) | ||||
| Any cardiac medication | 94.seven% (786) | 91.four% (198) | 95.viii% (588) | 0.03 |
| Anticongestive therapy‡ | 86% (843) | 82.two% (213) | 87.3% (630) | 0.07 |
| Antiarrhythmic therapy | 20.6% (462) | 13.7% (139) | 23.5% (323) | 0.02 |
| Angiotensin-converting enzyme inhibitor | 62.7% (461) | 60.9% (138) | 63.v% (323) | 0.60 |
| β-blocker | xiii.2% (461) | 15.ane% (139) | 12.4% (322) | 0.46 |
| Carnitine | 1.5% (461) | 0.7% (139) | 1.9% (322) | 0.68 |
Outcomes
We observed 99 events in the 223 patients with FDCM (22 deaths and 77 transplants) and 296 events in the 647 patients with IDCM (ninety deaths and 206 transplants). There was a significant difference in the cumulative incidence of pretransplant mortality; children with FDCM fared meliorate than those with IDCM (Gray test P=0.04; Fine–Greyness chance ratio (Hour) for pretransplant expiry 0.64; Figure 1A). The cumulative incidence of pretransplant death at 3 years postcardiomyopathy was 8.viii% (95 confidence interval [CI], 5.four%–13.2%) and fourteen.6% (95% CI, 11.8%–17.8%) in the FDCM and IDCM groups, respectively. However, the HR for pretransplant death in the FDCM versus IDCM groups subsequently adjustment for the presence of CHF at diagnosis did not differ from one (Hr, 0.71; 95% CI, 0.44–i.13; P=0.14; Table two).
| Outcome | due north | Predictor | Hazard Ratio (95% CI) | P Value* |
|---|---|---|---|---|
| Unadjusted models | ||||
| Death | 870 | Familial DCM vs idiopathic DCM | 0.64 (0.twoscore–ane.02) | 0.04/0.06 |
| Transplant | 870 | Familial DCM vs idiopathic DCM | 1.02 (0.78–ane.32) | 0.72/0.91 |
| Expiry/Transplant | 870 | Familial DCM vs idiopathic DCM | 0.85 (0.6–i.1) | 0.15 |
| Covariate-adapted models | ||||
| Death | 869 | Familial DCM vs idiopathic DCM | 0.71 (0.44–1.thirteen) | 0.fourteen |
| Presence of CHF at diagnosis | 2.36 (1.34–4.15) | 0.003 | ||
| Transplant | 698 | Familial DCM vs idiopathic DCM | 1.05 (0.76–one.44) | 0.77 |
| Historic period at diagnosis, y | 1.08 (1.06–1.11) | <0.001 | ||
| Presence of CHF at diagnosis | two.88 (one.88–4.43) | <0.001 | ||
| LVEDD z score at diagnosis | one.20 (one.13–1.27) | <0.001 | ||
| Decease/Transplant | 698 | Familial DCM vs idiopathic DCM | 0.97 (0.74–1.28) | 0.85 |
| Age at diagnosis, y | 1.06 (1.04–1.08) | <0.001 | ||
| Presence of CHF at diagnosis | three.45 (2.37–5.02) | <0.001 | ||
| LVEDD dimension z score at diagnosis | 1.13 (1.08–1.19) | <0.001 | ||
- Download figure
- Download PowerPoint
Figure 1. Competing outcomes assay showing estimated proportion of patients in 3 mutually sectional groups at all times later diagnosis (alive, transplanted, and died without transplant) in (A) familial dilated cardiomyopathy (CM) and (B) idiopathic dilated CM. Summation of proportions equals 1 at all time points.
At that place was no significant deviation in the cumulative incidence of transplant (P=0.72, Figure 1B), nor for the distributions for time to the composite outcome of death/transplant (P=0.15, Figure 2). The cumulative incidence of transplant at 3 years with pretransplant death as competing take a chance were 34.two% (95% CI, 27.5%–41.0%) and 36.1% (95% CI, 32.ane%–40.iii%) in the FDCM and IDCM groups, respectively (P=0.997). In covariate-adjusted models for the separate outcomes of pretransplant death and transplantation, in that location remained no departure between the FDCM and IDCM groups (Table 2).
- Download figure
- Download PowerPoint
Figure two. Kaplan–Meier curve comparing fourth dimension to decease and transplantation between children with familial dilated cardiomyopathy (FDCM) and idiopathic cardiomyopathy without a family history of cardiomyopathy (IDCM). Log-rank P=0.15; 395 events.
At three years subsequently diagnosis of cardiomyopathy, there was no difference in the proportion of children with echocardiographic normalization between patients with FDCM and those with IDCM (P=0.33). The rates were 30% versus 26%, respectively, at iii years. Nosotros institute no differences in medical therapy between the children with echo normalization and those without for both the IDCM and FDCM groups except that children with FDCM who did not have echo normalization were significantly more likely to receive anticongestive therapies (P<0.001).
Adventure Factors for Death/Transplant
Since there were no differences in fourth dimension to death or transplant between FDCM and IDCM groups, nosotros combined the groups and identified univariate risk factors for the composite upshot of time to death or transplantation since diagnosis (Table 3). The take a chance of death or transplant was associated with older historic period at diagnosis (HR, 1.03; 95% CI, ane.01%–1.05%). Diagnosis after 1 yr of age significantly increased the risk of death or transplant by well-nigh 40% (HR, ane.39; 95% CI, 1.14%–one.70%). The Hr for death or transplant was 3.18× as large for children with CHF at diagnosis as it was for those without (Tabular array three). For the subset of children with medication grade data, antiarrhythmic employ was associated with decease/transplant (60 minutes, ane.73; 95% CI, i.22%–two.46%). We identified an interaction (P=0.025) betwixt DCM blazon (FDCM versus IDCM) and but i clinical factor: LVEDD zscore. More abnormal dilation was a significant chance gene for both groups, simply the effect was stronger for children with FDCM (Hour, one.24; 95% CI, 1.14%–1.35% in FDCM versus Hr, 1.ten; 95% CI, 1.05%–1.16% in IDCM). However, for the entire accomplice the only contained predictors of death/transplant were those shown in the multivariable model in Table 2 (LVEDD z score without an interaction, CHF and older age at diagnosis).
| Characteristics | northward/% | Adventure Ratio (95% CI) | P Value |
|---|---|---|---|
| Type of dilated cardiomyopathy | 870 | 0.15 | |
| Familial dilated cardiomyopathy | 223 | Reference | |
| Idiopathic dilated cardiomyopathy | 647 | 1.18 (0.94–ane.49) | |
| Age at diagnosis, years | 870 | ane.03 (1.01–1.05) | <0.001 |
| Age ≥one y at diagnosis | 52.half dozen% (458/870) | 1.39 (1.14–1.70) | 0.001 |
| Male person | 50.6% (440/870) | 1.12 (0.92–1.36) | 0.28 |
| Race/ethnicity | 852 | 0.03 | |
| White | 462 | Reference | |
| Blackness | 181 | 1.15 (0.90–1.46) | |
| Hispanic | 147 | 0.71 (0.52–0.95) | |
| Other | 62 | 0.82 (0.53–i.25) | |
| CHF present at diagnosis | 74.half dozen% (648/869) | 3.18 (2.36–4.29) | <0.001 |
| Family history of sudden death | −ten.v% (76/727) | 1.01 (0.72–1.40) | 0.98 |
| Echocardiographic z scores | |||
| LV end-diastolic dimension | 699 | 1.14 (1.09–1.19) | <0.001 |
| LV cease-systolic dimension | 614 | 1.sixteen (i.10–1.21) | <0.001 |
| LV fractional shortening | 713 | 0.91 (0.87–0.94) | <0.001 |
| LV terminate-diastolic posterior wall thickness | 553 | 1.04 (0.99–i.09) | 0.xv |
| Terminate-diastolic septal thickness | 515 | 1.02 (0.95–1.09) | 0.67 |
| LV mass | 545 | 1.09 (i.05–1.13) | <0.001 |
Discussion
The study analyzes event and risk factors in patients with FDCM and DCM. The major finding is that the risk factors for the composite outcome of death or transplant are CHF and older age at diagnosis, particularly age at presentation older than one year increased the adventure of death or transplant by almost 40%; dilatation of the LV (LVEDD z score) was also a meaning risk factor for death or transplant. In the subsets of children with medications information available, we found that antiarrhythmic use was associated with an increment of expiry or transplant; this finding may reflect the fact that patients were sicker although the possibility of a proarrhythmic outcome cannot be excluded and caution should be used when starting these drugs. Our findings show that the pathogenesis of cardiomyopathy, FDCM, or IDCM was not a factor in determining the consequence; patient clinical characteristics are the major determinant.
Although there was no difference in outcome betwixt the FDCM and IDCM groups, we found that children with FDCM were significantly older at the time of diagnosis, less probable to present with heart failure, and more probable to take a positive family history of sudden cardiac decease than were children with IDCM. In addition, they showed less evidence of pathological LV remodeling at presentation as shown by significantly less, but withal abnormal, LV dilation, less septal thinning, and amend, but notwithstanding aberrant, LV function (LVFS or LVEF). Children with IDCM were more probable to be on cardiac medications and antiarrhythmic at diagnosis probably reflecting the fact that IDCM children were sicker at presentation as evidence that they were more likely to present with CHF.
Of children with either FDCM or IDCM, 26% to 30% experienced echocardiographic normalization over time, a finding consistent with normalization rates in a previous PCMR analysis of all patients with IDCM (regardless of family unit history).xiv
Our written report represents perhaps the largest report to date in children comparison clinical outcomes in FDCM and IDCM. In previous studies of patients with IDCM, further investigation of relatives found that betwixt xx% and fifty% of index cases had FDCM.15–xviii Although these studies were mostly of adults, they all included pediatric cases of DCM. In our study, of the 1832 cases of pure DCM in the PCMR database, 12% of children had a diagnosis of FDCM at their most recent follow-up. Similarly, in the National Australian Childhood Cardiomyopathy Study, the prevalence of FDCM in children anile <10 years was 14.7%.iii
Clear clinical or echocardiographic markers that differentiate FDCM from IDCM have been difficult to identify. FDCM cannot be reliably diagnosed in any individual child based solely on clinical (other than family history) or echocardiographic data, a finding consequent with other reports.xv,17,19 Even an accurate family history cannot necessarily identify FDCM at the time of diagnosis. Indeed, every bit illustrated past the PCMR feel, it is probable that a subset of the patients categorized as IDCM will be subsequently determined to take FDCM because of the manifestation of the disease in relatives at a later time and others may behave the aforementioned causative gene mutations despite the absence of a previous family history of DCM. Presently, the diagnosis of FDCM requires assembling a complete and accurate family unit history, as well as screening family members with echocardiography or another imaging modality. A recent review ended that proper screening of family members with echocardiography or other assessments of LV size and office volition detect FDCM in 20% to 35% of patients with IDCM.20 Genetic evaluation of these populations using newly available DCM genetic testing panels should improve identification of children with FDCM. Because most cases of IDCM are suspected to have a genetic crusade, evaluation of these children with clinically available DCM genetic testing panels is too important.
For many years, genetic testing for DCM in children has been used infrequently in clinical practice because of the loftier cost with traditional sequencing methods and the relatively depression probability of identifying a mutation in one of the many DCM genes. Even so, large cistron panels are now available as a result of the development of adjacent-generation sequencing approaches which can screen a larger number of genes simultaneously at lower cost and also result in a college number of positive results.20–22 Thus, incorporating genetic testing and genetic counseling into the intendance of patients with DCM is recommended.23,24 In an Australian prospective study of sudden cardiac death in children and young adults, the authors showed that genetic testing performed at autopsy was able to identify a likely cause of decease in 27% of the cases of unexplained sudden cardiac death.25 Although the toll-effectiveness of genetic testing in DCM has not nevertheless been evaluated, studies on the price-effectiveness of genetic testing in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and long QT syndrome indicate an overall benefit over screening via cardiac surveillance.26,27
Strengths and Limitations of the Study
The PCMR is the largest longitudinal study of cardiomyopathy in children, including more than iii,500 affected children. However, the diagnosis of FDCM or evidence of affected family members in children with IDCM was identified only from the medical record. Specifically, the diagnosis of FDCM was based on a annotation of FDCM in the medical record without any a priori PCMR requirement for data on detailed pedigrees or from comprehensive genetic testing (which has evolved considerably over the life of the PCMR) to establish a diagnosis of FDCM. It is of import to notation that family history is dynamic and needs to be revisited at each clinical encounter since children initially diagnosed as IDCM, may later be categorized as FDCM, given their updated family history or new genetic testing information. Related to this arroyo for identifying FDCM, it is possible that the patients in the FDCM group seem to accept better survival than IDCM because longer follow-upwardly allows more opportunity to exist classified as FDCM. Furthermore, screening echocardiograms of family members were non available. Medication class was only available for a subset of patients. Almost 30% of the IDCM cases in the PCMR could not be used in the analysis as a result of inconclusive family histories. Determining whether a patient has familial disease is often hard, and there is evidence that correct classification requires consequent and ongoing echocardiographic investigation of relatives, who may present with DCM at various ages.17,28 Finally, we institute no statistically meaning departure in the time to death/transplant (43% versus 51% for FDCM versus IDCM at 3 years). This deviation may exist considered clinically pregnant, but nosotros had limited statistical power considering of the shorter follow-upward time in the IDCM grouping.
Echocardiographic screening of relatives has shown that relying on family unit history alone to identify FDCM may not identify asymptomatic family members with cardiomyopathy or discover whether relatives reported to accept DCM may actually have had other cardiac diseases.28 Because our report relied solely on the family history establish in the medical record to make the diagnosis of FDCM, some children may have been misclassified with respect to final DCM category. Changes in clinical protocols addressing the acquisition and documentation of complete pedigrees and comprehensive family unit screening in this population during the grade of this report could too have afflicted the percent of children classified as FDCM.
Futurity Directions
Nigh one-half of our FDCM cases were not identified equally such at their initial clinical presentation. Our findings advise that at to the lowest degree the first-degree relatives of children presenting with DCM without a clear nonfamilial cause should undergo echocardiographic screening. In addition, country-of-the art clinical genetic testing of the proband, and if positive, of other family members, should be used to more than accurately make the diagnosis of FDCM in the affected child. Advances in clinical genetic testing for DCM, including the development of more comprehensive panels and cost-effective whole-genomic analysis, will eventually provide a more than rapid and definitive diagnosis of FDCM in children.
Conclusions
At diagnosis in both FDCM and IDCM, older age, the presence of CHF, and increased LV dilation are independently associated with poor outcomes. At the time of diagnosis, children eventually categorized as FDCM seem to exist at an earlier stage of the disease with less LV remodeling, and a lower prevalence of middle failure, when compared with children with IDCM.
In summary, recognition of FDCM is important nearly the implications for screening other family members, but not for the management of the afflicted individual, as the outcomes are related to patient factors, non whether the kid has FDCM or IDCM.
Acknowledgments
The authors thank the Children'southward Cardiomyopathy Foundation for its ongoing and consistent back up for the piece of work of the PCMR.
Sources of Funding
The PCMR is supported by grants from the National Heart, Lung, and Blood Institute (R01 HL53392, R01 HL111459, R01 HL109090; Dr Lipshultz, Principal Investigator) and the Children'due south Cardiomyopathy Foundation. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI.
Footnotes
References
- 1.
Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. . Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA . 2006; 296:1867–1876. doi: ten.1001/jama.296.fifteen.1867.CrossrefMedlineGoogle Scholar - 2.
Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. . The incidence of pediatric cardiomyopathy in 2 regions of the United States. N Engl J Med . 2003; 348:1647–1655. doi: 10.1056/NEJMoa021715.CrossrefMedlineGoogle Scholar - 3.
Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung K, Wilkinson LC, Davis AM, Kahler SG, Grub CW, Wilkinson JL, Weintraub RG ; National Australian Childhood Cardiomyopathy Written report. The epidemiology of childhood cardiomyopathy in Australia. Due north Engl J Med . 2003; 348:1639–1646. doi: 10.1056/NEJMoa021737.CrossrefMedlineGoogle Scholar - four.
Arola A, Jokinen E, Ruuskanen O, Saraste Thou, Pesonen E, Kuusela AL, Tikanoja T, Paavilainen T, Simell O. . Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol . 1997; 146:385–393.CrossrefMedlineGoogle Scholar - 5.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB ; American Center Association; Quango on Clinical Cardiology, Centre Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biological science Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Intendance and Outcomes Inquiry and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation . 2006; 113:1807–1816. doi: 10.1161/CIRCULATIONAHA.106.174287.LinkGoogle Scholar - 6.
Strauss A, Lock JE. . Pediatric cardiomyopathy–a long way to go. North Engl J Med . 2003; 348:1703–1705. doi: 10.1056/NEJMe030027.CrossrefMedlineGoogle Scholar - 7.
Cox GF, Sleeper LA, Lowe AM, Towbin JA, Colan SD, Orav EJ, Lurie PR, Messere JE, Wilkinson JD, Lipshultz SE. . Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics . 2006; 118:1519–1531. doi: 10.1542/peds.2006-0163.CrossrefMedlineGoogle Scholar - 8.
Alvarez JA, Orav EJ, Wilkinson JD, Fleming LE, Lee DJ, Sleeper LA, Rusconi PG, Colan SD, Hsu DT, Amble CE, Webber SA, Cox GF, Jefferies JL, Towbin JA, Lipshultz SE ; Pediatric Cardiomyopathy Registry Investigators. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. Apportionment . 2011; 124:814–823. doi: x.1161/CIRCULATIONAHA.110.973826.LinkGoogle Scholar - ix.
Sluysmans T, Colan SD. . Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol (1985) . 2005; 99:445–457. doi: 10.1152/japplphysiol.01144.2004.CrossrefMedlineGoogle Scholar - ten.
Colan SD, Parness IA, Spevak PJ, Sanders SP. . Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol . 1992; 19:619–629.CrossrefMedlineGoogle Scholar - xi.
Grey R. . A class of One thousand-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat . 1988; 16:1141–1154.CrossrefGoogle Scholar - 12.
Fine JP, Gray RJ. . A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc . 1999; 94:496–509.CrossrefGoogle Scholar - 13.
Austin PC, Lee DS, Fine JP. . Introduction to the analysis of survival data in the presence of competing risks. Circulation . 2016; 133:601–609. doi: 10.1161/CIRCULATIONAHA.115.017719.LinkGoogle Scholar - xiv.
Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. . Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular hazard burden. Am J Cardiol . 2002; xc:1284–1289.CrossrefMedlineGoogle Scholar - fifteen.
Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, Burnett JC, Rodeheffer RJ, Chesebro JH, Tazelaar Hard disk. . The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med . 1992; 326:77–82. doi: 10.1056/NEJM199201093260201.CrossrefMedlineGoogle Scholar - 16.
Mogensen J, Tater RT, Shaw T, Bahl A, Redwood C, Watkins H, Burke 1000, Elliott PM, McKenna WJ. . Astringent disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol . 2004; 44:2033–2040. doi: 10.1016/j.jacc.2004.08.027.CrossrefMedlineGoogle Scholar - 17.
Mestroni Fifty, Rocco C, Gregori D, Sinagra Chiliad, Di Lenarda A, Miocic S, Vatta Thousand, Pinamonti B, Muntoni F, Caforio AL, McKenna WJ, Falaschi A, Giacca M, Camerini . Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Center Muscle Disease Study Group. J Am Coll Cardiol . 1999; 34:181–190.CrossrefMedlineGoogle Scholar - 18.
Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, Towbin JA, Ware SM. . Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Carte du jour Fail . 2012; eighteen:396–403. doi: ten.1016/j.cardfail.2012.01.017.CrossrefMedlineGoogle Scholar - 19.
Moretti M, Merlo M, Barbati G, Di Lenarda A, Brun F, Pinamonti B, Gregori D, Mestroni L, Sinagra 1000. . Prognostic touch of familial screening in dilated cardiomyopathy. Eur J Heart Fail . 2010; 12:922–927. doi: ten.1093/eurjhf/hfq093.CrossrefMedlineGoogle Scholar - 20.
Hershberger RE, Siegfried JD. . Update 2011: clinical and genetic bug in familial dilated cardiomyopathy. J Am Coll Cardiol . 2011; 57:1641–1649. doi: 10.1016/j.jacc.2011.01.015.CrossrefMedlineGoogle Scholar - 21.
Morales A, Hershberger RE. . Genetic evaluation of dilated cardiomyopathy. Curr Cardiol Rep . 2013; 15:375. doi: 10.1007/s11886-013-0375-1.CrossrefMedlineGoogle Scholar - 22.
Metzker ML. . Sequencing technologies - the next generation. Nat Rev Genet . 2010; 11:31–46. doi: 10.1038/nrg2626.CrossrefMedlineGoogle Scholar - 23.
Ackerman MJ, Priori SG, Willems Southward, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Estimate DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. . HRS/EHRA skillful consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed equally a partnership between the Middle Rhythm Order (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm . 2011; 8:1308–1339. doi: ten.1016/j.hrthm.2011.05.020.CrossrefMedlineGoogle Scholar - 24.
Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA ; Heart Failure Society of America. Genetic evaluation of cardiomyopathy–a Heart Failure Gild of America practice guideline. J Bill of fare Fail . 2009; 15:83–97. doi: 10.1016/j.cardfail.2009.01.006.CrossrefMedlineGoogle Scholar - 25.
Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates Fifty, Lam 50, Davis AM, Thompson T, Connell V, Wallace J, Naylor C, Crawford J, Love DR, Hallam Fifty, White J, Lawrence C, Lynch Grand, Morgan N, James P, du Sart D, Puranik R, Langlois North, Vohra J, Winship I, Atherton J, McGaughran J, Skinner JR, Semsarian C. . A prospective report of sudden cardiac death among children and young adults. Northward Engl J Med . 2016; 374:2441–2452. doi: 10.1056/NEJMoa1510687.CrossrefMedlineGoogle Scholar - 26.
Wordsworth Due south, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H. . Deoxyribonucleic acid testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Center J . 2010; 31:926–935. doi: 10.1093/eurheartj/ehq067.CrossrefMedlineGoogle Scholar - 27.
Sabter-Molina M, Garcia-Molan Due east, Tovar I, Ruiz-Espejo F, Gimeno JR, Valdes M. . Cost effectiveness of genetic studies in inherited centre diseases. Cardiogenetics . 2013; 3: 28–xxx.Google Scholar - 28.
Johnson RA, Palacios I. . Dilated cardiomyopathies of the developed (beginning of ii parts). Northward Engl J Med . 1982; 307:1051–1058. doi: 10.1056/NEJM198210213071704.CrossrefMedlineGoogle Scholar
Our report represents maybe the largest study to date comparing clinical outcomes in familial dilated cardiomyopathy (FDCM) and idiopathic dilated cardiomyopathy (IDCM) in children. Nosotros found that children with FDCM were significantly older at the fourth dimension of diagnosis, less likely to nowadays with heart failure, and more probable to have a positive family history of sudden cardiac expiry than were children with IDCM. We found no covariate-adjusted difference between the FDCM and IDCM groups in time to death, transplant, or the combined end betoken of death/transplantation. They also had less evidence of pathological left ventricular (LV) remodeling at presentation every bit shown past significantly less, but nonetheless highly abnormal, LV dilation, less septal thinning, and better, but yet highly aberrant, LV function (LV fractional shortening or LV ejection fraction). Our findings suggest that at least the first-caste relatives of children presenting with DCM without a clear nonfamilial cause should undergo echocardiographic screening. In add-on, country-of-the fine art clinical genetic testing of both the proband, and if positive, of other family members, should be used to more than accurately make the diagnosis of FDCM in the afflicted child. Advances in clinical genetic testing for DCM, including the development of more than comprehensive genetic testing panels and toll-effective whole-genomic analysis, will eventually provide a more rapid and definitive diagnosis of FDCM in children. Considering most cases of IDCM are suspected to have a genetic cause, evaluation of these children with clinical available DCM genetic testing panels is likewise important. In summary, recognition of FDCM is of import regarding the implications for screening other family members, but not for the management of the affected individual, since the outcomes are related to patient factors, non whether the kid has FDCM or IDCM.
Source: https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.115.002637
0 Response to "How Are Children Affected by Familial Dilated Cardiomyopathy"
Post a Comment